Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
NK911 is a novel supramolecular nanocarrier designed for the enhanced delivery of doxorubicin (DXR) and is one of the successful polymer micelle systems to exhibit an efficient accumulation in solid tumours in mice. The purpose of this study was to define the maximum-tolerated dose (MTD) and dose-limiting toxicities (DLTs) of NK911 and to evaluate its pharmacokinetic profile in man. NK911 was given intravenously to patients with solid tumours every 3 weeks using an infusion pump at a rate of 10 mg DXR equivalent min(-1). The starting dose was 6 mg DXR equivalent m(-2), and the dose was escalated according to the accelerated titration method. A total of 23 patients participated in this study. Neutropenia was the predominant haematological toxicity, and grade 3 or 4 neutropenia was observed at doses of 50 and 67 mg m(-2). Common nonhaematological toxicities were mild alopecia, stomatitis, and anorexia. In the dose identification part of the study, DLTs were observed at a dose of 67 mg m(-2) (grade 4 neutropenia lasting more than 5 days). Thus, this dosage level was determined to be the MTD. Infusion-related reactions were not observed in any cases. The C(5 min) and area under the concentration curve parameters of NK911 exhibited dose-dependent characteristics. Among the 23 patients, a partial response was obtained in one patient with metastatic pancreatic cancer. NK911 was well tolerated and produced only moderate nausea and vomiting at myelosuppressive dosages. The recommended phase II dose was determined to be 50 mg m(-2) every 3 weeks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This same concept was used by Kataoka and colleagues in a series of works leading to development of polymeric micelle NK911, which was evaluated clinically [146, 147].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [146]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Self-citationTumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565 · cited 1×
“These characteristics, which are unique to solid tumours, constitute the basis of the enhanced permeability and retention (EPR) effect (Matsumura and Maeda, 1986; Maeda et al, 2000).”
BackgroundSelf-citationWHO Handbook for Reporting Results of Cancer Treatment
Palmer, M. K. (1982) · British Journal of Cancer · doi:10.1038/bjc.1982.83 · Cited by 2,198
Gabizón, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A., & Barenholz, Y. (1994) · PubMed · Cited by 1,382
Gordon, A. N., Fleagle, J. T., Guthrie, D., Parkin, D. E., Gore, M. E., & Lacave, A. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3312 · Cited by 1,211 · cited 2×
“No infusionrelated reactions, which are sometimes seen in cases of liposomal drug administration (Uziely et al, 1995; Muggia et al, 1996; Stewart et al, 1998; Gordon et al, 2001), occurred in this trial.”
BackgroundMuggia, F. M., Hainsworth, J. D., Jeffers, S., Miller, P., Groshen, S., Tan, M., Roman, L., Uziely, B., Muderspach, L., Garcia, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.987 · Cited by 647 · cited 2×
“No infusionrelated reactions, which are sometimes seen in cases of liposomal drug administration (Uziely et al, 1995; Muggia et al, 1996; Stewart et al, 1998; Gordon et al, 2001), occurred in this trial.”
BackgroundAccelerated Titration Designs for Phase I Clinical Trials in Oncology
Simon, R., Rubinstein, L., Arbuck, S. G., Christian, M. C., Freidlin, B., & Collins, J. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.15.1138 · Cited by 639 · cited 2×
“Dose escalation was performed according to the previously described accelerated titration method (Simon et al, 1997).”
MethodDevelopment of the polymer micelle carrier system for doxorubicin
Nakanishi, T., Fukushima, S., Okamoto, K., Suzuki, M., Matsumura, Y., Yokoyama, M., Okano, T., Sakurai, Y., & Kataoka, K. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00341-8 · Cited by 570 · cited 7×
“The hydrophobic inner core enables NK911 to entrap a sufficient amount of DXR. NK911 has a diameter of about 40 nm (Nakanishi et al, 2001).”
BackgroundMethodSelf-citationUziely, B., Jeffers, S., Isacson, R., Kutsch, K., Wei-Tsao, D., Yehoshua, Z., Libson, E., Muggia, F. M., & Gabizon, A. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1777 · Cited by 477 · cited 1×
“No infusionrelated reactions, which are sometimes seen in cases of liposomal drug administration (Uziely et al, 1995; Muggia et al, 1996; Stewart et al, 1998; Gordon et al, 2001), occurred in this trial.”
Background(1991) · PubMed · Cited by 418
Cited by
Items 301–400 of 621
Zhang, J., Li, S., & Li, X. (2009) · Recent Patents on Nanotechnology · doi:10.2174/187221009789177803 · Cited by 42
Ravichandran, R., Venugopal, J. R., Sundarrajan, S., Mukherjee, S., Sridhar, R., & Ramakrishna, S. (2012) · Materials Science and Engineering C · doi:10.1016/j.msec.2012.04.024 · Cited by 39
Nanoformulations of doxorubicin: how far have we come and where do we go from here?
Borišev, I. Đ., Mrdjanović, J., Petrović, D., Seke, M., Jović, D., Čonić, B. S., Latinovic, N., & Djordjevic, A. N. (2018) · Nanotechnology · doi:10.1088/1361-6528/aac7dd · Cited by 38
Rational nanocarrier design towards clinical translation of cancer nanotherapy
Guo, D., Ji, X., & Luo, J. (2021) · Biomedical Materials · doi:10.1088/1748-605x/abe35a · Cited by 40
Gou, M., Shi, H., Guo, G. F., Men, K., Zhang, J., Zheng, L., Li, Z., Luo, F., Qian, Z., Zhao, X., et al. (2011) · Nanotechnology · doi:10.1088/0957-4484/22/9/095102 · Cited by 40
“Because of the decreased cytotoxicity, a high dose of drug in the micelles should be applied, hence resulting in problems of drug accumulation in other tissues and effects on metabolism [41, 42].”
BackgroundBarros, S. D. M., Whitaker, S. K., Sukthankar, P., Avila, L. A., Gudlur, S., Warner, M., Beltrão, E. I. C., & Tomich, J. M. (2016) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2016.02.027 · Cited by 44
Guan, S., Chang, J., Cheng, C., Luo, T., Ho, A., Wang, C., Wu, C.-T., & Liu, S. (2014) · Oncotarget · doi:10.18632/oncotarget.2050 · Cited by 39
“Currently, several polymeric micelles-formulated antitumor drugs were investigated in clinical trials, including paclitaxel, cisplatin, doxorubicin, and SN-38 [40-43].”
BackgroundAhmad, Z., Tang, Z., Shah, A., Lv, S., Zhang, D., Zhang, Y., & Chen, X. (2014) · Macromolecular Bioscience · doi:10.1002/mabi.201400109 · Cited by 38
Miller, T., Hill, A., Uezguen, S., Weigandt, M., & Goepferich, A. (2012) · Biomacromolecules · doi:10.1021/bm3002045 · Cited by 37
Shi, C., Sun, Y., Wu, H., Zhu, C., Wei, G., Li, J., Chan, T., Ouyang, D., & Mao, S. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.08.054 · Cited by 38
Nanoparticles for cosmetic use and its application
Chiari‐Andréo, B. G., de Almeida-Cincotto, M. G. J., Oshiro, J. A., Taniguchi, C. Y. Y., Chiavacci, L. A., & Isaac, V. L. B. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816504-1.00013-2 · Cited by 45
A short circulating peptide nanofiber as a carrier for tumoral delivery
Wagh, A. V., Singh, J., Qian, S. Y., & Law, B. (2012) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2012.10.009 · Cited by 38
Abolmaali, S. S., Tamaddon, A. M., Salmanpour, M., Mohammadi, S., & Dinarvand, R. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.04.009 · Cited by 39
Wang, T., Yang, S., Mei, L. A., Parmar, C. K., Gillespie, J. W., Praveen, K. P., Petrenko, V. A., & Torchilin, V. P. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0052 · Cited by 35
“7), micelles formed by a copolymer of polyethylene glycol (PEG) and doxorubicin-conjugated poly (aspartic acid; NK911; ref.”
BackgroundDrug Delivery Using Nanocarriers: Indian Perspective
Gupta, S., & Kumar, P. (2012) · Proceedings of the National Academy of Sciences India Section B Biological Sciences · doi:10.1007/s40011-012-0080-7 · Cited by 39
“Cationic formulations have been described to affect cell proliferation, differentiation, and pro-apoptotic genes in human epithelial cells [285].”
Sotoudegan, F., Amini, M., Faizi, M., & Aboofazeli, R. (2016) · PubMed Central · Cited by 57
Xu, D. S., Li, E., Karmakar, B., Awwad, N. S., Ibrahium, H. A., Osman, H.-E. H., El-kott, A. F., & Abdel‐Daim, M. M. (2021) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2021.103638 · Cited by 40
Zhang, H., Li, T., Luo, W., Peng, G. X., & Xiong, J. (2021) · Journal of Experimental Nanoscience · doi:10.1080/17458080.2021.2007886 · Cited by 37
Biomedical Nanotechnology for Cancer
Pope‐Harman, A., Cheng, M. M., Robertson, F. M., Sakamoto, J. H., & Ferrari, M. (2007) · Medical Clinics of North America · doi:10.1016/j.mcna.2007.05.008 · Cited by 39
Polymeric micelles: a ray of hope among new drug delivery systems
Kapse, A., Anup, N., Patel, V., Saraogi, G. K., Mishra, D. K., & Tekade, R. K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814487-9.00006-5 · Cited by 51
Theranostics for Triple-Negative Breast Cancer
Choi, H. R., & Kim, K. (2023) · Diagnostics · doi:10.3390/diagnostics13020272 · Cited by 42
“FDA approval for Kaposi sarcoma or ovarian cancer treatment [54].”
BackgroundIn vivo evaluation of novel chitosan graft polymeric micelles for delivery of paclitaxel
Liu, J., Li, H., Chen, D., Jin, X., Zhao, X., Zhang, C., & Ping, Q. (2010) · Drug Delivery · doi:10.3109/10717544.2010.520355 · Cited by 34
“Furthermore, they had been evaluated in several clinical trials as carriers for anti-cancer drugs (Mizumura et al., 2002; Danson et al., 2004; Matsumura et al., 2004).”
BackgroundTopoisomerases: Resistance versus Sensitivity, How Far We Can Go?
Bansal, S., Bajaj, P., Pandey, S., & Tandon, V. (2016) · Medicinal Research Reviews · doi:10.1002/med.21417 · Cited by 36
Nanomicelles in Diagnosis and Drug Delivery∗
Trinh, H. M., Joseph, M. A., Cholkar, K., Mitra, R., & Mitra, A. K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42978-8.00003-6 · Cited by 51
Cai, L., Qiu, N., Li, X., Luo, K., Chen, X., Yang, L., He, G., Wei, Y., & Chen, L. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.01.042 · Cited by 33
Guo, H., & Mi, P. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1988 · Cited by 37
Wakaskar, R. R., Bathena, S. P., Tallapaka, S. B., Ambardekar, V. V., Gautam, N., Thakare, R. N., Simet, S. M., Curran, S. M., Singh, R. K., Dong, Y., et al. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1515-z · Cited by 37
Controlled Multi‐functionalization Facilitates Targeted Delivery of Nanoparticles to Cancer Cells
Hudlikar, M. S., Li, X., Gagarinov, I. A., Kolishetti, N., Wolfert, M. A., & Boons, G. (2015) · Chemistry - A European Journal · doi:10.1002/chem.201503999 · Cited by 36
Yee, Y. J., Benson, H. A., Dass, C. R., & Chen, Y. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121499 · Cited by 35
Passive vs. Active Targeting: An Update of the EPR Role in Drug Delivery to Tumors
Upponi, J. R., & Torchilin, V. P. (2014) · Advances in delivery science and technology · doi:10.1007/978-3-319-08084-0_1 · Cited by 43
Seki, T., Fang, J. Q., & Maeda, H. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0131-6_3 · Cited by 36
Dai, Y., Wang, S., Shi, W., & Lang, M. (2017) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2017.08.011 · Cited by 33
“…hydrogels to reduce the side effects of chemotherapy (Ta & Proter, 2013; Zhao et al., 2016; Chen, Alberti, & Kalia, 2016; Hamaguchi et al., 2005; Matsumura et al., 2004; Uchino et al., 2005; El-Sherbiny & Smyth, 2010), and apatinib-encapsulated nanoparticles have been shown a promising effect…”
BackgroundTalelli, M., Rijcken, C. J. F., Oliveira, S., van der Meel, R., Henegouwen, P. M. P. V. B. E., Lammers, T., van Nostrum, C. F., Storm, G., & Hennink, W. E. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.06.003 · Cited by 34
Serras, A. S., Faustino, C. M. C., & Pinheiro, L. M. V. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16081047 · Cited by 35
Nanodevices for studying nano-pathophysiology
Cabral, H., Miyata, K., & Kishimura, A. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.06.003 · Cited by 36
Block Copolymer Nanostructures and Their Applications: A Review
Singh, A. N., Thakre, R. D., More, J. C., Sharma, P. K., & Agrawal, Y. K. (2015) · Polymer-Plastics Technology and Engineering · doi:10.1080/03602559.2014.986811 · Cited by 34
Elsabahy, M., Samarajeewa, S., Raymond, J. E., Clark, C., & Wooley, K. L. (2013) · Journal of Materials Chemistry B · doi:10.1039/c3tb20668h · Cited by 30
Du, N., Guo, W., Yu, Q., Guan, S., Guo, L., Shen, T., Tang, H., & Gan, Z. (2016) · Polymer Chemistry · doi:10.1039/c6py01113f · Cited by 32
Bioinspired poly(cation-π) micelles drug delivery platform for improving chemotherapy efficacy
Tan, G., Wang, Y., He, Y., Miao, G., Li, Y., & Wang, X. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.07.016 · Cited by 32
d’Arcy, R., Mohtadi, F. E., Francini, N., DeJulius, C. R., Back, H., Gennari, A., Geven, M. A., Lopez‐Cavestany, M., Turhan, Z. Y., Yu, F. Z., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c09232 · Cited by 32
Cheng, F., Guan, X., Cao, H., Su, T., Cao, J., Chen, Y., Cai, M., He, B., Gu, Z., & Luo, X. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.07.031 · Cited by 34
Histological study on side effects and tumor targeting of a block copolymer micelle on rats
Kawaguchi, T., Honda, T., Nishihara, M., Yamamoto, T., & Yokoyama, M. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.02.011 · Cited by 33
A spotlight on alkaloid nanoformulations for the treatment of lung cancer
Sindhoor, S. M., Naveen, N. R., Rao, G. K., Gopan, G., Chopra, H., Park, M. N., Alshahrani, M. M., Jose, J., Emran, T. B., & Kim, B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.994155 · Cited by 34
Photodynamic therapy-mediated remote control of chemotherapy toward synergistic anticancer treatment
Li, Y., Lv, S., Song, Z., Dang, J., Li, X., He, H., Xu, X., Zhou, Z., & Yin, L. (2018) · Nanoscale · doi:10.1039/c8nr03611j · Cited by 28
Zhang, Y., Zhang, X., Chen, W., He, Y., Liu, Y., & Ju, H. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.06.028 · Cited by 30
Chen, J., Karmakar, B., Salem, M. A., Alzahrani, A. Y. A., Bani‐Fwaz, M. Z., Abdel‐Daim, M. M., & El-kott, A. F. (2022) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2021.103681 · Cited by 29
The spatiotemporal journey of nanomedicines in solid tumors on their therapeutic efficacy
Qin, M., Xia, H., Xu, W., Chen, B., & Wang, Y. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115137 · Cited by 33
Costamagna, F., Hillaireau, H., Vergnaud, J., Clarisse, D., Jamgotchian, L., Loreau, O., Denis, S., Gravel, E., Doris, E., & Fattal, E. (2019) · Nanoscale · doi:10.1039/c9nr08714a · Cited by 28
Sakai‐Kato, K., Ishikura, K., Oshima, Y., Tada, M., Suzuki, T., Ishii‐Watabe, A., Yamaguchi, T., Nishiyama, N., Kataoka, K., Kawanishi, T., et al. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.12.022 · Cited by 30
Synthesis and characterization of modified starch hydrogels for photodynamic treatment of cancer
Saboktakin, M. R., Tabatabaie, R. M., Ostovarazar, P., Maharramov, A. M., & Рамазанов, М. А. (2012) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2012.06.024 · Cited by 29
Qiu, L., Zhang, L., Zheng, C., & Wang, R. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22468 · Cited by 27
Nano-Aggregates: Emerging Delivery Tools for Tumor Therapy
Sharma, V. K., Jain, A., & Soni, V. (2013) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2013007706 · Cited by 27
Liposomes: Ideal drug delivery systems in breast cancer
Forouhari, S., Beygi, Z., Mansoori, Z., Hajsharifi, S., Heshmatnia, F., & Hayat, S. M. G. (2021) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2253 · Cited by 29
Gregori, M., Bertani, D., Cazzaniga, E., Orlando, A., Mauri, M., Bianchi, A., Re, F., Sesana, S., Minniti, S., Francolini, M., et al. (2015) · Macromolecular Bioscience · doi:10.1002/mabi.201500172 · Cited by 27
Pearce, A. K., Anane‐Adjei, A. B., Cavanagh, R. J., Monteiro, P. F., Bennett, T. M., Taresco, V., Clarke, P., Ritchie, A., Alexander, M. R., Grabowska, A. M., et al. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202000892 · Cited by 30
Effects of stability of PEGylated micelles on the accelerated blood clearance phenomenon
Su, Y., Liu, M., Xiong, Y., Ding, J., Liu, X., Song, Y., & Deng, Y. (2018) · Drug Delivery and Translational Research · doi:10.1007/s13346-018-0588-3 · Cited by 27
Cancer stem cells and nanomedicine: new opportunities to combat multidrug resistance?
Dalpiaz, A., Paganetto, G., Botti, G., & Pavan, B. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.07.023 · Cited by 28
Ha, P. T., Tran, T. M. N., Pham, H. D., Nguyen, Q. H., & Nguyen, X. P. (2010) · Advances in Natural Sciences Nanoscience and Nanotechnology · doi:10.1088/2043-6254/1/1/015012 · Cited by 26
Araki, T., Kono, Y., Ogawara, K., Watanabe, T., Ono, T., Kimura, T., & Higaki, K. (2012) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b12-0020 · Cited by 29
Current Update on the Role of Enhanced Permeability and Retention Effect in Cancer Nanomedicine
Jasim, A. A., Abdelghany, S., & Greish, K. F. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809717-5.00002-6 · Cited by 33
Zhang, G., & Jiang, X. (2019) · Polymers · doi:10.3390/polym11020316 · Cited by 26
“Up to now, three polyaspartamide anti-tumor formulations Polymers 2019, 11, 316; doi:10.3390/polym11020316 www.mdpi.com/journal/polymers Polymers 2019, 11, 316 2 of 14 derived from L-aspartic acid (NK105 [17], NK911 [18] and NC6300 [19,20]) have been approved for clinical trials.”
InfluentialPolymeric Micelles for Drug Delivery
Wu, W., & Jiang, X. (2016) · Wiley eBooks · doi:10.1002/9783527694396.ch3 · Cited by 28
Harada, Y., Yamamoto, T., Sakai, M., Saiki, T., Kawano, K., Maitani, Y., & Yokoyama, M. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.11.016 · Cited by 27
Chen, J., Xing, M. M. Q., & Zhong, W. (2011) · Polymer · doi:10.1016/j.polymer.2010.12.056 · Cited by 25
Doxorubicin conjugates: a practical approach for its cardiotoxicity alleviation
Ibrahim, A. A., Nsairat, H., Al-Sulaibi, M., El‐Tanani, M., Jaber, A. M., Lafi, Z., Barakat, R., Abuarqoub, D. A., Mahmoud, I. S., Obare, S. O., et al. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2343882 · Cited by 26
“Non-hematological toxicities such as nausea and vomiting were modest [216].”
BackgroundTang, J., Bian, Z., Hu, J., Xu, S., & Liu, H. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.12.048 · Cited by 24
Pharmaceutical Micelles: Combining Longevity, Stability, and Stimuli Sensitivity
Carstens, M. G., Rijcken, C. J. F., van Nostrum, C. F., & Hennink, W. E. (2008) · Fundamental biomedical technologies · doi:10.1007/978-0-387-76554-9_9 · Cited by 31
“Some of these micellar formulations have already entered clinical trials and showed promising results with regard to their therapeutic index in cancer patients (Barratt, 2000; Kim et al., 2004; Matsumura et al., 2004; Torchilin, 2006).”
BackgroundIn situ measurements of polymer micellization kinetics with millisecond temporal resolution
Kalkowski, J., Liu, C., Leon-Plata, P., Szymusiak, M., Zhang, P., Irving, T., Shang, W., Bilsel, O., & Liu, Y. (2019) · Macromolecules · doi:10.1021/acs.macromol.8b02257 · Cited by 23
Seitz, S., Buchholz, S., Schally, A. V., Jayakumar, A. R., Weber, F., Papadia, A., Rick, F. G., Szalontay, L., Treszl, A., Köster, F., et al. (2012) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32835a7e29 · Cited by 23
Nanoparticle Drug Delivery Can Reduce the Hepatotoxicity of Therapeutic Cargo
Yang, F., Medik, Y. B., Li, L., Tian, X., Fu, D., Brouwer, K. L. R., Wagner, K., Sun, B., Sendi, H., Mi, Y., et al. (2020) · Small · doi:10.1002/smll.201906360 · Cited by 24
Purgatorio, R., Boccarelli, A., Pisani, L., de Candia, M., Catto, M., & Altomare, C. (2024) · Antioxidants · doi:10.3390/antiox13010133 · Cited by 23
Yin, J., Li, Z., Yang, T., Wang, J., Zhang, X., & Zhang, Q. (2010) · Journal of drug targeting · doi:10.3109/10611861003663531 · Cited by 23
“So far, six polymeric micellar formulations are currently in different stages of clinical trials in various countries (Danson et al., 2004; Kim et al., 2004; Matsumura et al., 2004; Hamaguchi et al., 2005; Uchino et al., 2005).”
BackgroundA smart micellar system with an amine-containing polycarbonate shell
Wang, H.-F., Luo, X., Liu, C.-W., Feng, J., Zhang, X., & Zhuo, R. (2011) · Acta Biomaterialia · doi:10.1016/j.actbio.2011.08.030 · Cited by 24
Polymer Micelles for Drug Delivery
Kim, S., & Park, K. (2010) · CRC Press eBooks · doi:10.1201/9781420087734-c19 · Cited by 27
Naka, S., Vinh, N., Cabral, H., Murayama, H., Kaida, S., Kataoka, K., Morikawa, S., & Tani, T. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s81339 · Cited by 23
“22–27 Moreover, the integration of tracer functions for clinical imaging, including computed tomography, magnetic resonance imaging (MRI), single-photon emission computed tomography, and positron emission tomography, with anticancer drugs allows the construction of polymeric micelle carriers for…”
Phillips, M. C., & Mousa, S. A. (2022) · Nanomedicine · doi:10.2217/nnm-2021-0361 · Cited by 24
Liu, R., He, B., Li, D., Lai, Y., Tang, J. Z., & Gu, Z. (2012) · Polymer · doi:10.1016/j.polymer.2012.02.013 · Cited by 23
Nanomedicine: pharmacological perspectives
Bhattacharya, S., Alkharfy, K. M., Janardhanan, R., & Mukhopadhyay, D. (2012) · Nanotechnology Reviews · doi:10.1515/ntrev-2011-0010 · Cited by 21
“The safety of vehicles prepared using these agents may further facilitate their development for use in a variety of highly morbid and mortality causing diseases [92, 93] .”
BackgroundPolymeric Micelles for Formulation of Anti-Cancer Drugs
Lee, H., Soo, P. L., Liu, J., Butler, M., & Allen, C. J. (2006) · CRC Press eBooks · doi:10.1201/9781420006636-17 · Cited by 35
Liu, M., Luo, X., Qiu, Q., Kang, L., Li, T., Ding, J., Xiong, Y., Zhao, Z., Zan, J., Chang, C., et al. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00687 · Cited by 21
Effects of simvastatin on the PXR signaling pathway and the liver histology in Mugilogobius abei
Wang, C., Ku, P., Nie, X., Bao, S., Wang, Z., & Li, K. (2018) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2018.09.133 · Cited by 21
Seitz, S., Schally, A. V., Treszl, A., Papadia, A., Rick, F. G., Szalontay, L., Szepesházi, K., Ortmann, O., Halmos, G., Hohla, F., et al. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32832d190b · Cited by 21
Current State-of-the-Art and New Trends in Self-Assembled Nanocarriers as Drug Delivery Systems
Paliwal, H., Parihar, A., & Prajapati, B. G. (2022) · Frontiers in Nanotechnology · doi:10.3389/fnano.2022.836674 · Cited by 21
Cellular mechanism of oral absorption of solidified polymer micelles
Abramov, E., Cassiola, F. M., Schwob, O., Karsch-Bluman, A., Shapero, M., Ellis, J. L., Luyindula, D., Adini, I., D’Amato, R. J., & Benny, O. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.07.008 · Cited by 21
Meng, H., Zou, Y., Zhong, P., Meng, F., Zhang, J., Cheng, R., & Zhong, Z. (2017) · Macromolecular Bioscience · doi:10.1002/mabi.201600518 · Cited by 21
Feng, S., Zhou, J., Li, Z., Appelman, H. D., Zhao, L., Zhu, J., & Wang, T. D. (2019) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2019.110498 · Cited by 21
Proteins and Poly(Amino Acids)
Saxena, T. K., Karumbaiah, L., & Valmikinathan, C. M. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-396983-5.00003-x · Cited by 23
Hide, D., Gil, M., Andrade, F., Rafael, D. F. D. S., Raurell, I., Bravo, M., Barberá, A., Gracia‐Sancho, J., Vargas, V., Augustín, S., et al. (2020) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2020.102267 · Cited by 25
Chang, Z., Karmakar, B., Lu, H., Lou, X., Alkhayyat, S. S., Mostafa‐Hedeab, G., Batiha, G. E., El-kott, A. F., Elsaid, F. G., Al‐Kahtani, M. A., et al. (2022) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2022.103858 · Cited by 19
Drug delivery systems in the transport of doxorubicin
Matyszewska, D. (2014) · Surface Innovations · doi:10.1680/si.13.00040 · Cited by 22
Drug delivery strategies for cathepsin inhibitors in joint diseases
Wang, D., & Brömme, D. (2005) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2.6.1015 · Cited by 21
“Based on this principle, many colloidal drug delivery systems have been developed for improved cancer chemotherapy with many in clinical trials [77-79].”
BackgroundDancey, J. E., Freidlin, B., & Rubinstein, L. (2006) · doi:10.1002/0470861258.ch4 · Cited by 19
Development of nanoparticulate systems with action in breast and ovarian cancer: nanotheragnostics
Cunha, F. D. S., Pereira, L. N. D. S., Silva, T. P. D. C. E., Luz, R. A. S., & Mendes, A. N. (2018) · Journal of drug targeting · doi:10.1080/1061186x.2018.1523418 · Cited by 20
The Landscape of Nanovectors for Modulation in Cancer Immunotherapy
Volovăț, S. R., Lupaşcu-Ursulescu, C. V., Gheorghe, L., Volovat, C. D., Boboc, D., Scripcariu, D. V., Amurariti, F., Ştefănescu, C., Stolniceanu, C. R., Agop, M., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020397 · Cited by 26
Red blood cells based nanotheranostics: A smart biomimetic approach for fighting against cancer
Misra, R., & Sharath, N. S. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124401 · Cited by 20
Tian, S., Liu, G., Wang, X., Zhang, G., & Hu, J. (2016) · Polymers · doi:10.3390/polym8060226 · Cited by 19
“On the other hand, it is generally accepted that supramolecular assemblies are subjected to high dilution and vigorous shearing force after intravenous administration, likely deforming or even disintegrating the supramolecular assemblies [21–23], which may lead to premature drug release and thus systemic toxicity [24–…”
BackgroundWang, T., Tang, X., Han, J., Ding, Y., Guo, W., & Pei, M. (2016) · Macromolecular Bioscience · doi:10.1002/mabi.201500413 · Cited by 19
Wei, X., Liu, Y., El-kott, A. F., Ahmed, A. E., & Khames, A. (2021) · Journal of Saudi Chemical Society · doi:10.1016/j.jscs.2021.101343 · Cited by 18
Preparation, Drug Release, and Cell Growth Inhibition of a Gelatin: Doxorubicin Conjugate
Wu, D. C., Cammarata, C. R., Park, H. J., Rhodes, B. T., & Ofner, C. M. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1065-9 · Cited by 18
“DOX has been investigated in several macromolecular delivery systems such as liposomes (2), synthetic copolymers of N-(2-hydroxypropyl)methacrylamide (HPMA) (3,4) other synthetic water soluble polymers (5), micelles (6,7), polysaccharides (8) as well as block copolymer vesicles (or polymersomes) (9,10).”
Mechanistically elucidating the in vitro safety and efficacy of a novel doxorubicin derivative
Alrushaid, S., Zhao, Y., Sayre, C. L., Maayah, Z. H., Forrest, M. L., Senadheera, S. N., Chaboyer, K., Anderson, H. D., El‐Kadi, A. O. S., & Davies, N. M. (2017) · Drug Delivery and Translational Research · doi:10.1007/s13346-017-0379-2 · Cited by 22
Metadata
- Authors
- Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Okusaka, T., Ueno, H., Ikeda, M., & Watanabe, N.
- Affiliations
- National Cancer Center Hospital East (JP)
- National Cancer Center Hospital (JP)
- Nippon Kayaku (Japan) (JP)
- Corresponding author
- Matsumura, Y
- Venue
- British Journal of Cancer
- Published
- 2004-10-12
- Volume
- 91
- Issue
- 10
- Pages
- 1775-1781
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2410050
- OpenAlex
- W2056347214
- Cited by
- 623
- References
- 17
- Citations by year
- 2026: 10 · 2025: 11 · 2024: 20 · 2023: 18 · 2022: 28 · 2021: 35 · 2020: 28 · 2019: 23 · 2018: 25 · 2017: 37 · 2016: 42 · 2015: 38 · 2014: 53 · 2013: 28 · 2012: 54
- FWCI
- 8.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- doxorubicin, polymeric micelles, supramolecular nanocarriers, maximum tolerated dose, dose-limiting toxicity, neutropenia, pharmacokinetics, solid tumors, metastatic pancreatic cancer, accelerated titration, recommended phase 2 dose, drug delivery
- MeSH terms
- Aged, Antineoplastic Agents, Doxorubicin, Drug Administration Schedule, Female, Humans, Male, Micelles, Middle Aged, Nausea, Neoplasms, Neutropenia, Peptides, Polyethylene Glycols, Vomiting, Maximum Tolerated Dose
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.